<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161208031300N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-05-11</date_registration>
      <primary_sponsor>Bojnourd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of resistance training and nano curcumin supplementation on synovial fluid biomarkers</public_title>
      <acronym></acronym>
      <scientific_title>Study of the effect of resistance training and nano curcumin supplementation on synovial fluid biomarkers in patients with knee osteoarthritis.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30319</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Other design features: According to our knowledge, to date, there have been very limited studies in the field of resistance training with the use of nanocurcumin supplementation in patients with knee osteoarthritis.Investigating changes in the level of inflammatory and cartilage factors in synovial fluid , we will show a more accurate comparison of the effects of resistance training and the effect of supplementation of nano-corcomin alone and simultaneously, Randomization description: Randomization is done with random numbers, Blinding description: The medication and placebo are coded by the investigator and distributed randomly among the patients.Researchers, clinical caregivers, evaluators, and analysts do not know what type of supplement they are using.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee Osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Patients with  Knee Osteoarthritis who use nano-curcumin supplementation with resistance training.Exercise groups for 2 months, 3 days a week, knee and hip exercises, including knee extension, pelvic abduction, pelvic edema and plantar flexion, and quadrice chairs, then with a intensity of 50-75% 1RM, will last until the endurance.nano-curcumin  supplement of the company Sinacurcumin with a dose of 1000 mg (equivalent to 80 mg of nanosilver), and daily 1, and placebo daily 1(soft gelatin capsule). Intervention 2: Second intervention group : Patients with  Knee Osteoarthritis who take a placebo with their resistance training .The training groups will perform for 2 months, 3 days a week, knee and hip exercises, including knee extension, pelvic abduction, pelvic edema and plantar flexion, and quadrice chairs, then with a intensity of 50-75% 1RM until the pressure is tolerated. Placebo. Intervention 3: Third intervention group:Patients with  Knee Osteoarthritis that use supplement nano-curcumin.Nanocorcinol supplements are produced by the company Sinacurcumin at a dose of 1000 mg (equivalent to 80 mg Nanosciences) and daily 1 tablet. Intervention 4: Control group: Patients with Knee Osteoarthritis who use one placebo per day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the main outcome of this study will be shared through the article.

When:
The start of the access period will be 3  month after the results are printed.

To whom:
Researchers working in academia and academics and industry professionals

Conditions:
Terms of use of data or documentation:1. Having specialized knowledge and academic competence in the research subject 2. Present actual research results 3. Failure to remove or modify the original address of the authors of scientific articles 4. Observe the interests of stakeholders at all stages 5. No publication of the results of the plan without coordination and obtaining a license

Where to obtain:
1- Dr. Reza Ganji: r.ganji@nkums.ac.ir
2. Dr. Sadegh Cheragh Birjand: s_birjandi2001@yahoo.com

How to obtain:
Applicants for documentation and data files can apply to the announced email addresses by sending a valid academic and academic application.After verifying the documents submitted, the documents and data files will be provided to the applicants.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farideh Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Street of the Uprising, No. 322, opposite the Guardian Council</address>
        <city>Bojnurd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9414974877</zip>
        <telephone>+98 58 3222 8105</telephone>
        <email>farideh.haghighi.1351@gmail.com</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza ganji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mohagher Alley,Shahid Beheshti St, , Research and Technology Dept. of North Khorasan University of Medical Sciences</address>
        <city>Bojnurd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9414974877</zip>
        <telephone>+98 58 3229 6966</telephone>
        <email>r.ganji@nkums.ac.ir</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having an OA (primary) knee with a grade of 1 to 4
Low mobility (Participate in sports activities less than three times a week for less than 20 minutes during the past six months and lack of participation in organized activities over the past year)
The age range is between 45-60 years
Non-acute illness like cardiovascular disease and lack of fracture and injury In the lower extremity or a joint infection
Lack of endocrine and metabolic diseases (diabetes, thyroid, kidney, liver), cardiovascular disease (high blood pressure, coronary artery disease and atherosclerosis, peripheral vascular diseases and myocardial infarction), mental illness (depression, Schizophrenia and mania), epilepsy, anemia, cancer and any infectious disease.
No history of alcohol and smoking and any addiction</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness of patients to continue cooperation in research
No synovial fluid during aspiration
Knee joint limitation and inability to perform sports exercises
Any injuries when doing exercises
Taking medications other than diclofenac for the treatment of osteoarthritis
Suffering from cardiovascular, liver, diabetes, kidney failure
Age range less than 45 and more than 60 years
Addiction and alcohol and smoking
Joint infection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary gonarthrosis, bilateral</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Patients with  Knee Osteoarthritis who use nano-curcumin supplementation with resistance training.Exercise groups for 2 months, 3 days a week, knee and hip exercises, including knee extension, pelvic abduction, pelvic edema and plantar flexion, and quadrice chairs, then with a intensity of 50-75% 1RM, will last until the endurance.nano-curcumin  supplement of the company Sinacurcumin with a dose of 1000 mg (equivalent to 80 mg of nanosilver), and daily 1, and placebo daily 1(soft gelatin capsule).</i_keyword>
      <i_keyword>Second intervention group : Patients with  Knee Osteoarthritis who take a placebo with their resistance training .The training groups will perform for 2 months, 3 days a week, knee and hip exercises, including knee extension, pelvic abduction, pelvic edema and plantar flexion, and quadrice chairs, then with a intensity of 50-75% 1RM until the pressure is tolerated. Placebo</i_keyword>
      <i_keyword>Third intervention group:Patients with  Knee Osteoarthritis that use supplement nano-curcumin.Nanocorcinol supplements are produced by the company Sinacurcumin at a dose of 1000 mg (equivalent to 80 mg Nanosciences) and daily 1 tablet.</i_keyword>
      <i_keyword>Control group: Patients with Knee Osteoarthritis who use one placebo per day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Levels of synovial fluid biomarkers of the knee. Timepoint: 24 hours before the intervention and 48 hours after the end of the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Knee pain. Timepoint: 24 hours before the intervention and 24 hours after the intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index,Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Improving the quality of life. Timepoint: 24 hours before the intervention and 24 hours after the intervention. Method of measurement: Health Assessment Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bojnourd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-03-13</approval_date>
        <contact_name>Ethics Committee of Bojnourd University of Medical Sciences</contact_name>
        <contact_address>Shahid Mohagher Alley,Shahid Beheshti St, Research and Technology Dept. of North Khorasan University of Medical Sciences Bojnurd North Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
